Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

.2016 Jul 15:6:29791.
doi: 10.1038/srep29791.

Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease

Affiliations

Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease

Ting Zhang et al. Sci Rep..

Erratum in

Abstract

The prevalence of Clostridium difficile infection (CDI) in patients suffering from inflammatory bowel disease (IBD) has increased rapidly over the past several decades in North America and Europe. However, the exact global epidemiology remains unclear because of insufficient data from developing countries. A total of 646 hospitalized adult IBD patients were enrolled; and their fresh stool specimens were obtained and used for Clostridium difficile detection. The incidence of CDI in Crohn's disease (CD) patients (12.7%) was significantly lower than that in Ulcerative disease (UC) patients (19.3%). Among the toxin types, A(+)B(+) strain was the most common. Length of stay, hospitalization frequency and bowel surgery rate were significantly higher in the CDI than in the non-CDI group in CD or UC patients. More patients in CDI-CD group were still in active and even clinical moderate or severe CD stage than non-CDI-CD group after 2 years of following-up. Fistula, antibiotics and infliximab usage likely increased the CDI rate in CD patients, Infliximab treatment was considered a risk factor in UC patients. CDI is an exacerbating public health issue that may influence IBD course, increase expenditures, and delay the remission of IBD patients. IBD patients with CDI require urgent attention.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Overview diagram of theC. difficile infection cases included in this study.
Figure 2
Figure 2. ClinicalC. difficile infection in IBD patients.
(A)C. difficile positive rate in CD was significantly lower than that in UC patients(12.7% vs 19.3%, *P = 0.022); (B) toxin type distribution ofC. difficile strains according to IBD severity.
Figure 3
Figure 3. Pictures of the different agarose gels of the PCR products.
M, molecular marker; The numbers represent different samples negative or positive for the gene considered and do not refer to the same samples on different gels. (A) PCR products oftcdA(1, negative sample; 3, positive sample) andtcdB(2 and 4, positive samples) gene; (B) PCR products of thetpi gene indicating the presence ofC. difficile; (C) 16S r RNA gene PCR products.
See this image and copyright information in PMC

References

    1. Seksik P. et al.. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 24 Suppl 3, 11–18 (2006). - PubMed
    1. Nguyen G. C., Kaplan G. G., Harris M. L. & Brant S. R. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 103, 1443–1450 (2008). - PubMed
    1. Meyer A. M., Ramzan N. N., Loftus E. J., Heigh R. I. & Leighton J. A. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 38, 772–775 (2004). - PubMed
    1. Goodhand J. R., Alazawi W. & Rampton D. S. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 33, 428–441 (2011). - PubMed
    1. Bernstein C. N. et al.. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 16, 112–124 (2010). - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp